Gilead will be donating up to 2.4 million bottles of Truvada (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg tablets) to the Centers for Disease Control and Prevention (CDC) in an effort to provide access to the preexposure prophylaxis (PrEP) therapy to uninsured Americans at risk for HIV.
Truvada is approved in combination with safer sex practices for HIV-1 PrEP to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents who are HIV-negative and weigh ≥35kg. The donation will extend through 2030 and will include Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg tablets), currently being reviewed by the Food and Drug Administration (FDA) for use as PrEP, if it is approved.
Findings from the 2-year DISCOVER study demonstrated that once-daily Descovy was non-inferior to Truvada for prevention of HIV-1 infection. Data from the trial was included in the supplemental New Drug Application (sNDA) for Descovy, which is receiving Priority Review from the FDA.
Commenting on the initiative, Gregg Alton, Chief Patient Officer, Gilead Sciences said, “We believe today’s donation, combined with efforts to address the root causes of the epidemic, such as racism, violence against women, stigma, homophobia and transphobia, can play an important role in ending the HIV epidemic in the United States, particularly in parts of the country with the highest burden of disease.”
For more information visit Gilead.com.
This article originally appeared on MPR